TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6364882
Drug: Oral trimeprazine
Normalized name: trimeprazine
DrugBank: Alimemazine (DB01246)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral trimeprazine plus droperidol
Study: 6364882
Drug: Oral trimeprazine
Normalized name: trimeprazine
DrugBank: Alimemazine (DB01246)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral trimeprazine
Study: 31221697
Drug: GLP-1Ra treatment
Normalized name: IL-1RA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: GLP-1Ra treatment for 3 months
Study: 30627180
Drug: Budesonide nebulizer
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide nebulizer suspension (Pulmicort Nebulizer)
Study: 30627180
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension (Pulmicort Turbuhaler)
Study: 27632179
Drug: Ezetimibe (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe (10 mg daily oral administration, n = 209)
Study: 10229249
Drug: Intracutaneous sterile
Normalized name: Steril-Eyes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracutaneous sterile water injections (ISW)
Study: 7890212
Drug: Gorging pattern
Normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gorging pattern (two meals daily)
Study: 7890212
Drug: Nibbling pattern
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nibbling pattern (four to seven meals daily)
Study: 1979541
Drug: Acrivastine administered
Normalized name: Acrivastine
DrugBank: Acrivastine (DB09488)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acrivastine administered 30, 45, 60 or 90 min before challenge
Study: 30415988
Drug: Adjuvant modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant modified FOLFIRINOX (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, irinotecan 180 mg/m2, and 5‐FU 2.4 g/m2 over 46 hours) every 2 weeks for 24 weeks (12 cycles)
Study: 30415988
Drug: Modified FOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified FOLFOX6 (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5‐FU bolus 400 mg/m2, then 2.4 g/m2 over 46 hours) every 2 weeks for 24 weeks (12 cycles)
Study: 25384542
Drug: Bifocal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifocal treatment of myopia
Study: 18505372
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg oral clodronate (Bonefos) daily over 3 years
Study: 15513572
Drug: Combined growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined growth hormone (GH) and GnRH analogue treatment
Study: 15513572
Drug: GnRH analogue
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH analogue treatment alone
Study: 9295978
Drug: Endoscopy at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopy at the end of initial treatment (group 1)
Study: 9295978
Drug: No endoscopy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No endoscopy at the end of initial treatment (group 2)
Study: 3537216
Drug: 5-day pulse
Normalized name: DULSE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day pulse chemotherapy every 3 weeks (group I)
Study: 3537216
Drug: Continuous chemotherapy
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous chemotherapy (group C)
Study: 3537216
Drug: Semi-continuous chemotherapy
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semi-continuous chemotherapy (group G)
Study: 6366137
Drug: 3 years
Normalized name: NanoVM 1-3 years
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 years of chemotherapy
Study: 20805344
Drug: Early class
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early class III protraction facemask treatment (PFG)
Study: 20805344
Drug: Control/no treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control/no treatment (CG)
Study: 18937608
Drug: Patient-controlled sedation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled sedation (PCS) with propofol bolus of 0.25 mg kg(‐1); no lockout interval; n = 50
Study: 18937608
Drug: Anesthesiologist-controlled sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthesiologist-controlled sedation (ACS) with continuous infusion of propofol 1% (3 mg kg(‐1) h(‐1); n = 50)
Study: 15674406
Drug: Spironolactone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (25 mg/day)
Study: 7575256
Drug: 0.3% ofloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% ofloxacin solution
Study: 10707137
Drug: Fortified tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fortified tobramycin (1.5%) and cefazolin (10%) solutions (control group)
Study: 8550186
Drug: Monoclonal antibody
Normalized name: Monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody (MAb) 61BG 1.3, 3 micrograms per tooth, applied at 1, 3, 7, and 10 days after suppression of P. gingivalis.
Study: 8550186
Drug: Monoclonal antibody
Normalized name: Monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody (MAb) 61BG 1.3
Study: 1841774
Drug: High-dose verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose verapamil treatment (Isoptin RR, 240 mg verapamil, twice daily)
Study: 6138074
Drug: Vesparax (barbiturate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vesparax (barbiturate combination)
Study: 31172446
Drug: GDC-0276 single
Normalized name: GDC-0425
DrugBank: GDC-0425 (DB14791)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDC-0276 single doses (SD) of 2–270 mg (PIC) and 45–540 mg (CD)
Study: 31172446
Drug: GDC-0276 multiple
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GDC-0276 multiple doses (MD) of 15–540 mg divided into two or three doses/day
Study: 26879545
Drug: Intraperitoneal paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intraperitoneal paclitaxel (PTX) at 60 mg/m2 on the day of surgery and on days 14, 21, 28, 42, 49, and 56
Study: 26879545
Drug: Intravenous paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous paclitaxel (PTX) at 80 mg/m2 on the same schedule
Study: 25703611
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality exposure therapy for PTSD
Study: 16917560
Drug: Amoxicillin/Clavulanate
Normalized name: AMOXICILLIN/CLAVULANATE
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin/Clavulanate
Study: 12791225
Drug: Topical ophthalmic
Normalized name: MIOTICS,TOPICAL OPHTHALMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ophthalmic NSAIDs
Study: 8915645
Drug: ADCON-L Anti-Adhesion
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADCON-L Anti-Adhesion Barrier Gel
Study: 1871184
Drug: Evening primrose
Normalized name: EVENING PRIMROSE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening primrose oil (EPO) supplementation (45 mg GLA and 360 mg linoleic acid, 2 capsules daily for 4 months, then 4 capsules daily for 4 months)
Study: 6137500
Drug: Prazosin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (4 mg, 2 pills of Minipress Pfizer per day) for 7 days
Study: 31425171
Drug: Pharmacist-led hypertension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led hypertension management program with barbers promoting follow-up and pharmacists prescribing antihypertensive therapy.
Study: 27779354
Drug: Parecoxib 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parecoxib 0.25 mg·kg‐1
Study: 27779354
Drug: Parecoxib 1
Normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib 1 mg·kg‐1
Study: 27779354
Drug: Parecoxib 2
Normalized name: parecoxib 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parecoxib 2 mg·kg‐1
Study: 27779354
Drug: Parecoxib (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parecoxib (various doses)
Study: 23486511
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (20 g)
Study: 23909813
Drug: Glucose (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (10 g)
Study: 24314863
Drug: Glucose (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (20 g)
Study: 17994473
Drug: Intranasal cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal cocaine (4, 20, 40, and 60 mg) during aripiprazole maintenance
Study: 16400891
Drug: Epinephrine (2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine (2, 4, and 8 actuations administered at 17‐minute intervals)
Study: 16400891
Drug: Albuterol (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (6 cumulative actuations administered at 17‐minute intervals)
Study: 16310974
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus contingency management (CM)
Study: 8573426
Drug: Tiludronate 400
Normalized name: tiludronate
DrugBank: Tiludronic acid (DB01133)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiludronate 400 mg/day for 3 months
Study: 12669742
Drug: Etidronate 400
Normalized name: etidronate 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etidronate 400 mg/day
Study: 2229455
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg velnacrine tid for 28 days
Study: 2229455
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg velnacrine bid
Study: 2229455
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg velnacrine bid
Study: 2229455
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg velnacrine bid
Study: 29431126
Drug: Sham rTMS
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham rTMS treatment (Control)
Study: 26056438
Drug: Low-threshold physical
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-threshold physical activity program (60 minutes weekly for 20 weeks)
Study: 22680774
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy (i.v., mg/m(2), vindesine 5, adriamycin 90, BCNU 140, etoposide 600, methylprednisolone 600) before radiotherapy (RT)
Study: 22232850
Drug: Etoricoxib 60
Normalized name: etoricoxib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 60 mg (test product: Etocox-60)
Study: 22232850
Drug: Etoricoxib 60
Normalized name: etoricoxib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 60 mg (reference product)
Study: 22232850
Drug: Etoricoxib 60
Normalized name: etoricoxib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 60 mg (test product: Etocox-60) and reference product
Study: 19770831
Drug: Cavinton 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cavinton 30 mg/day for 90 days (2 courses per year) in addition to basic therapy
Study: 19770831
Drug: Cavinton treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cavinton treatment
Study: 12044619
Drug: Sustained-release morphine
Normalized name: morphine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release morphine (20mg/d titrated to a maximum of 180mg/d)
Study: 7842195
Drug: Both therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both therapies (Oxygen and Dopamine)
Study: 731810
Drug: estramustine-17-phosphate (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: estramustine-17-phosphate (600 mg daily for at least 3 months)
Study: 731810
Drug: 2.6‐cis-diphenylhexamethylcyclotetrasiloxane (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.6‐cis-diphenylhexamethylcyclotetrasiloxane (300 mg daily for at least 3 months)
Study: 29398993
Drug: Pregabalin 150
Normalized name: pregabalin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 150 mg daily
Study: 25295709
Drug: Procalcitonin (PCT)
Normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procalcitonin (PCT) algorithm with 0.1 ng/ml cut-off
Study: 23623623
Drug: In-Home Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-Home Cognitive Behavioral Therapy (IH-CBT)
Study: 18548362
Drug: Beta-alanine (4.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-alanine (4.8 g per day)
Study: 15706558
Drug: Whole body
Normalized name: MaxiVision Whole Body Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole body vibration plus physical therapy (PT)
Study: 7698053
Drug: 9 g
Normalized name: Publix Pen Needle 29 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 g of fish oil
Study: 7698053
Drug: 18 g
Normalized name: flotufolastat F 18 gallium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 g of fish oil
Study: 7698053
Drug: 9 g
Normalized name: Publix Pen Needle 29 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 g of corn oil
Study: 7698053
Drug: 18 g
Normalized name: flotufolastat F 18 gallium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 g of corn oil
Study: 2655680
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone sodium succinate (MPSS) at doses of 20, 40, and 80 mg
Study: 2655680
Drug: Oral methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methylprednisolone (20 mg as 4 x 5 mg tablets)
Study: 31285821
Drug: WHO EBHR
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: WHO EBHR formulation with 0.5% glycerol
Study: 31285821
Drug: WHO EBHR
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: WHO EBHR formulation without glycerol (0%)
Study: 31285821
Drug: WHO EBHR
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: WHO EBHR formulation with 1.45% glycerol
Study: 31285821
Drug: WHO EBHR
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: WHO EBHR formulation with 0.75% glycerol
Study: 27831503
Drug: cisplatin-paclitaxel (chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: cisplatin-paclitaxel (chemotherapy group)
Study: 17518508
Drug: Cinacalcet (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet (90 mg) alone
Study: 17518508
Drug: Cinacalcet (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet (90 mg) with ketoconazole (200 mg twice daily for 7 days)
Study: 17518508
Drug: Cinacalcet (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet (90 mg) with ketoconazole
Study: 12628619
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for nicotine dependence
Study: 9879639
Drug: 14C-delmopinol mouth
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14C-delmopinol mouth rinse (10-ml aqueous solution at 2 mg/ml)
Study: 9879639
Drug: 14C-delmopinol oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14C-delmopinol oral dose
Study: 31742932
Drug: Propel steroid
Normalized name: Propel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propel steroid eluting stents (packing type B)
Study: 20141367
Drug: Alendronate 70
Normalized name: ALENDRONATE 70MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 70 mg once weekly for 1 year
Study: 20141367
Drug: Risedronate 35
Normalized name: risedronate 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 35 mg once weekly for 1 year
Study: 10969426
Drug: Weekly home-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly home-based intervention
Study: 10969426
Drug: Control (brief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (brief monthly tracking visits)
Study: 9102666
Drug: Multiple insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple insulin therapy
Study: 8416458
Drug: Amoxicillin 3
Normalized name: amoxicillin 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 3 g orally plus probenecid 1 g orally
Study: 6134959
Drug: Spectinomycin 2
Normalized name: spectinomycin 2 g intramuscular powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spectinomycin 2 g IM
Study: 2877490
Drug: Colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal bismuth subcitrate (CBS), 120 mg 4 times a day
Study: 2877490
Drug: Cimetidine (C),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (C), 400 mg 3 times a day
Study: 2877490
Drug: Cimetidine (C),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (C), 400 mg at meals plus 800 mg at bedtime
Study: 30173431
Drug: 100 U
Normalized name: vitamin E 100 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 U botulinum‐A toxin at 10 U/ml
Study: 30173431
Drug: 100 U
Normalized name: vitamin E 100 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 U botulin‐A toxin at 10 U/ml
Study: 22712629
Drug: Memantine 5
Normalized name: memantine 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine 5 mg once daily, titrated to 10 mg twice daily for 11 days, then DMQ 30 mg every 12 hours for 8 days
Study: 22712629
Drug: DMQ 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMQ 30 mg every 12 hours for 8 days, then memantine titrated to 10 mg every 12 hours for 11 days
Study: 18587135
Drug: IL-2 at
Normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-2 at 4.5 MIU twice daily in 5 day cycles
Study: 18587135
Drug: IL-2 at
Normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-2 at 7.5 MIU twice daily in 5 day cycles
Study: 10663618
Drug: High-dose IL-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IL-2
Study: 11788552
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml meat soup meal
Study: 9895382
Drug: PEG (13
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG (13 g/sachet)
Study: 9895382
Drug: Lactulose (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose (10 g/sachet)
Study: 8562673
Drug: 0.8 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 ml/kg alcohol
Study: 2371929
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate (30 ml)
Study: 7395881
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of lidocaine or placebo
Study: 31987229
Drug: 500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/day of synbiotic for 8 weeks
Study: 31407653
Drug: Annual community-wide
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual community-wide treatment (CWT) for four years
Study: 31407653
Drug: Biennial school-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biennial school-based treatment (SBT) over four years
Study: 28300854
Drug: THVD-102 (oxybutynin
Approvals — FDA: no, EMA: no, PMDA: no
Description: THVD-102 (oxybutynin 7.5 mg / pilocarpine 7.5 mg)
Study: 15605184
Drug: IV/PO moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV/PO moxifloxacin (400 mg q.i.d.)
Study: 15605184
Drug: IV/PO antimicrobial
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV/PO antimicrobial comparator agents
Study: 9005910
Drug: Postoperative epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative epidural infusion of 5 microg/ml fentanyl
Study: 9005910
Drug: Postoperative epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative epidural infusion of 5 microg/ml fentanyl plus 0.125% bupivacaine at a rate of 10 ml per hour
Study: 31229619
Drug: Oral GABA
Normalized name: GABA
DrugBank: gamma-Aminobutyric acid (DB02530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral GABA twice daily plus two injections of recombinant GAD enzyme
Study: 31229619
Drug: Oral GABA
Normalized name: GABA
DrugBank: gamma-Aminobutyric acid (DB02530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral GABA plus placebo GAD injections
Study: 29485791
Drug: IV‐PCA with
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV‐PCA with morphine
Study: 15657666
Drug: PTP injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTP injection into intersphincteric space and internal anal sphincter with guidance by endoanal ultrasound (Group A, n = 42)
Study: 15657666
Drug: PTP injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTP injection into intersphincteric space and internal anal sphincter without guidance by endoanal ultrasound (Group B, n = 40)
Study: 18359127
Drug: Tacrolimus ointment
Normalized name: Tacrolimus Ointment
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus ointment (0.03% or 0.1%)
Study: 9761513
Drug: RenaGel (calcium-
Approvals — FDA: no, EMA: no, PMDA: no
Description: RenaGel (calcium- and aluminium-free phosphate binder), starting doses of one, two, or three 500-mg capsules three times per day with meals for 8 weeks.
Study: 9761513
Drug: RenaGel treatment
Normalized name: RenaGel
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RenaGel treatment
Study: 7800969
Drug: OM-85 BV
Normalized name: OM-85 BV
DrugBank: OM85 (DB16533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OM-85 BV (oral administration)
Study: 7800969
Drug: OM-85 BV
Normalized name: OM-85 BV
DrugBank: OM85 (DB16533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OM-85 BV (injection)
Study: 3364402
Drug: UV-A (320-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: UV-A (320-400 nm) doses of 17.8 +/- 1.9 J/cm2 to the anterior side and 21.0 +/- 3.3 J/cm2 to the posterior side, with UV-B (280-320 nm) doses equivalent to 10% of UV-A doses.
Study: 28532870
Drug: High repetitive,
Approvals — FDA: no, EMA: no, PMDA: no
Description: High repetitive, high dosage medical exercise therapy (MET), n=16
Study: 28532870
Drug: Low dosage
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dosage exercise therapy (ET), n=17
Study: 25466662
Drug: Nutritional supplements
Normalized name: nutritional supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplements (600 kcal, 20 g/d protein) and intensive rehabilitation program